TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
HHS announced an interim enforcement-discretion policy for licensed pharmacies and physicians compounding six peptides under specified conditions. The policy is not FDA approval, and an oncologist writing in MedPage Today says clinical evidence on safety and effectiveness remains limited, including questions about BPC-157 and cancer-related pathways.
HHS announced on October 28 an interim enforcement-discretion policy covering the compounding of six experimental peptides, opening a conditional regulatory path for licensed pharmacies and physicians while the FDA considers formal rulemaking. The policy is not FDA approval and does not establish that the substances are safe or effective, a distinction oncologist Gilberto de Lima Lopes Jr. emphasized in a MedPage Today commentary published November 10.
The substances named in the policy are BPC-157, MOTS-c, TB-500, KPV, Semax and Epitalon. Under specified conditions, HHS said the government does not intend to take enforcement action against licensed pharmacies and physicians compounding them. The stated safeguards include appropriately sourced ingredients, documentation of identity and purity, single-ingredient preparations, labeling, reporting of serious adverse events and prescriptions written for individual patients.
The policy followed a July meeting of the FDA’s Pharmacy Compounding Advisory Committee. The committee voted eight to six, with one abstention, to recommend BPC-157 for the compounding list and endorsed five of the other six substances it considered. FDA reviewers, however, found insufficient evidence to support adding any of the seven substances under review. Their briefing materials cited limited or absent human safety data for several peptides and concerns about product characterization.
Lopes, an oncologist who has conducted clinical trials, said the policy’s safeguards could address some risks associated with products from poorly regulated online suppliers. He cautioned that controls over ingredients and purity answer a different question from whether a substance is safe or benefits patients. The source report says Nevada regulators imposed $35,000 in fines on four parties after two women became seriously ill following peptide injections at a 2025 event; investigators could not establish the cause or verify the injected products’ contents.
Access Expands Before Evidence
The policy could make some experimental peptides more accessible through licensed compounding, even as evidence about their effects in people remains limited. That matters to patients seeking treatments for injuries, recovery or aging because a regulated preparation may appear more established than a product bought online, although the policy does not certify clinical benefit.
Lopes raised a specific concern about BPC-157 and angiogenesis, the formation of new blood vessels. Experimental studies suggest the peptide may affect pathways involved in that process, which supports tissue repair but is also used by some tumors. He did not claim BPC-157 causes cancer or promotes tumor growth; he said human evidence is insufficient to determine whether such effects occur, particularly with prolonged exposure or in people with current or past cancer.
The broader issue is how to balance access and oversight. Compounding can meet an individual patient’s needs, but Lopes warned that prescribing similar experimental products to many people for common wellness purposes can resemble commercial drug distribution without the evidence normally expected of an approved medicine.
Products Worth Considering
Withings Body Scan Smart Scale with Segmental Body Composition and ECG, Black
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms up to 1875 ft², Quiet 27 dB Operation, AHAM VERIFIDE Certified, Air Quality Monitor,
Fitbit Sense 2 Health and Fitness Smartwatch, Shadow Grey/Graphite
As an affiliate, we earn on qualifying purchases.
Evidence and the Compounding Review
The October policy came amid debate over whether certain peptides should be eligible for compounding. The advisory committee’s recommendations were not the same as FDA approval: the FDA reviewers’ briefing materials described evidence gaps, including an inability to establish BPC-157’s effectiveness for ulcerative colitis, the condition considered in that review.
Lopes noted a possible mismatch between that reviewed indication and much commercial interest in BPC-157, which he said includes tendon injuries, exercise recovery and anti-aging. Results for one condition cannot establish safety or effectiveness for another, especially when dose, route and duration of use differ. He also argued that promising biological mechanisms or findings in animals do not establish benefit in humans.
The policy’s ingredient and documentation safeguards address product identity and quality, but those are separate from clinical questions. A certificate of analysis may help establish what a preparation contains; it does not show that the product improves health. Safety studies and well-designed clinical trials are needed to answer different questions about harm and benefit.
Safety Questions Still Open
The policy does not resolve whether the six peptides are safe or effective for particular conditions. The source report does not provide the full text of the policy or specify every condition attached to enforcement discretion. It also does not describe a completed FDA rulemaking decision, so the substances’ longer-term regulatory status remains unsettled.
For BPC-157, Lopes said there is not enough human evidence to determine whether the peptide affects cancer risk or progression. That is a concern to investigate, not evidence that harm has been established. More broadly, product composition was a concern in the reported 2025 Nevada incident: investigators could not obtain the injected products for laboratory testing, and the exact contents and cause of the women’s severe reactions remain unverified.
It is also unclear from the supplied source how widely pharmacies and physicians will use the policy, what patient monitoring will look like in practice, or whether prospective clinical studies will follow. The available material does not establish the peptides’ long-term effects or show that the policy itself requires trials.
FDA Rulemaking and Clinical Evidence
The next regulatory milestone is the FDA’s consideration of formal rulemaking for the substances. The source material does not give a timetable for that process. Until further decisions are made, HHS’s interim policy applies under specified conditions; it should not be read as a finding that the peptides have proven benefits.
Lopes called for a more efficient review process and further investigation of potential risks, including questions tied to cancer-related pathways. For patients and clinicians, the key developments to watch are any FDA rulemaking decisions, clearer evidence about the identity and purity of compounded products, and human studies that examine safety and effectiveness for specific uses.
Key Questions
Does the HHS policy mean the six peptides are FDA-approved?
No. The policy is an interim enforcement-discretion policy for compounding under specified conditions. It does not amount to FDA approval or establish safety and effectiveness.
Which peptides are covered by the policy?
The six named substances are BPC-157, MOTS-c, TB-500, KPV, Semax and Epitalon.
What is the oncologist’s concern about BPC-157 and cancer?
Lopes cited experimental research suggesting BPC-157 may affect angiogenesis, the formation of new blood vessels. Because tumors can also use blood-vessel growth, he said the possibility warrants study. He did not say human evidence shows BPC-157 causes cancer or tumor progression.
What did FDA reviewers say about the evidence?
The FDA briefing materials found insufficient evidence to support adding any of the seven substances considered. The review cited limited or absent human safety data for several peptides and product-characterization concerns.
What remains to be decided?
The FDA is considering formal rulemaking, but the source material gives no timetable. Evidence about the peptides’ human safety and effectiveness, their long-term effects and their use for different conditions also remains incomplete.
Source: medpagetoday.com
